Regional differences in physicians’ behavior and factors influencing the intensity of PCSK9 inhibitor therapy with alirocumab: a subanalysis of the ODYSSEY APPRISE study

BACKGROUND: Despite better accessibility of the effective lipid-lowering therapies, only about 20% of patients at very high cardiovascular risk achieve the low-density lipoprotein cholesterol (LDL-C) goals. There is a large disparity between European countries with worse results observed for the Cen...

Descripción completa

Detalles Bibliográficos
Autores principales: Banach, Maciej, Lewek, Joanna, Pol, Kaja, Rabczenko, Daniel, Balanescu, Serban M., Blaha, Vladimir, Ceska, Richard, Jankowski, Piotr, Surma, Stanisław, Kolovou, Genovefa, Liberopoulos, Evangelos, Mitu, Florin, Mitu, Magda, Naji, Franjo Husam, Paragh, Gyorgy, Popławska, Magdalena, Vrablik, Michal, Pella, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315496/
https://www.ncbi.nlm.nih.gov/pubmed/37404744
http://dx.doi.org/10.3389/fcvm.2023.1206551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10315496/
https://www.ncbi.nlm.nih.gov/pubmed/37404744
http://dx.doi.org/10.3389/fcvm.2023.1206551

Ejemplares similares